Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.46 |
| ▸ | FDPS | P14324 | 3/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.45 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3942651 | 1.00 | CA1 (0.52) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL3946026 | 0.97 | CA1 (0.54) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL3940035 | 0.90 | — | — | |
| SCHEMBL10942476 | 0.82 | CA1 (0.54) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL20520253 | 0.82 | CA1 (0.54) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL2301401 | 0.82 | CA1 (0.54) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL20520255 | 0.82 | CA1 (0.54) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL20520239 | 0.82 | CA1 (0.54) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL1279390 | 0.82 | CA1 (0.54) | CA1ACE2FFAR1FFAR4GPR84 | |
| SCHEMBL502907 | 0.82 | CA1 (0.54) | CA1ACE2FFAR1FFAR4GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4710491-A | N-glycosylated carboxylic acid derivatives as agents for combating rheumatic diseases | TROPONWERKE GMBH & CO., KG (DE) | 1987-12-01 | — | — | US | claimed |
| EP-2046147-B1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2013-05-01 | — | — | EP | disclosed |
| US-20090311403-A1 | Method of Using Organic Compounds | GIVAUDAN SA (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-2046147-A1 | METHOD OF USING ORGANIC COMPOUNDS | Givaudan SA (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7378551-B2 | Amide compound | KAO CORPORATION (JP) | 2008-05-27 | — | — | US | disclosed |
| WO-2008011742-A1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-31 | — | — | WO | disclosed |
| US-20070185208-A1 | Amide compound | KAO CORPORATION (JP) | 2007-08-09 | — | — | US | disclosed |
| US-5872111-A | TOILET BAR SOAP, FACIAL BODY CLEANSER, SHAMPOO, CONDITIONER, COSMETIC,SHAVING CREAM OR LOTION, SHOWER GEL, FABRIC SOFTENING CONDITIONER, AND UNDERARM DEODORANT/ANTI-PERSPIRANT | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| EP-0140321-B1 | USE OF DERIVATIVES OF AMIDES OF CARBOXYLIC ACIDS IN WHICH THE N ATOM IS SUBSTITUTED BY A GLYCOSYL RADICAL AS GROWTH PROMOTOR IN ANIMAL NUTRITION | BAYER AG (DE) | 1989-04-12 | — | — | EP | disclosed |
| US-4710491-A | N-glycosylated carboxylic acid derivatives as agents for combating rheumatic diseases | TROPONWERKE GMBH & CO., KG (DE) | 1987-12-01 | — | — | US | disclosed |
| US-4683222-A | STIMULANTS FOR IMMUNE SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1987-07-28 | — | — | US | disclosed |
| US-4680287-A | N-glycosylated carboxamide derivatives as growth-promoters in livestock feeding | BAYER AKTIENGESELLSCHAFT (DE) | 1987-07-14 | — | — | US | disclosed |
| EP-0091645-B1 | DERIVATIVES OF AMIDES OF CARBOXYLIC ACIDS IN WHICH THE N ATOM IS SUBSTITUTED BY A GLYCOSYL RADICAL, METHOD FOR THEIR PREPARATION AND THEIR USE TO INFLUENCE THE IMMUNOGENIC SYSTEM | BAYER AG (DE) | 1987-02-25 | — | — | EP | disclosed |
| EP-0147777-A2 | Derivatives of M-glycosylated amides of carboxylic acids as a product for combating diseases of the rheumatism type | Troponwerke GmbH & Co. KG (DE) | 1985-07-10 | — | — | EP | disclosed |
| EP-0140321-A2 | Use of derivatives of amides of carboxylic acids in which the N atom is substituted by a glycosyl radical as growth promotor in animal nutrition | BAYER AG (DE) | 1985-05-08 | — | — | EP | disclosed |
| EP-0091645-A1 | Derivatives of amides of carboxylic acids in which the N atom is substituted by a glycosyl radical, method for their preparation and their use to influence the immunogenic system | BAYER AG (DE) | 1983-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185208-A1 | Amide compound | H1-0, H1-2, H1-4 | CA1 4192/4885ACE2 4560/4885FFAR1 88/4885 |
| US-20090311403-A1 | Method of Using Organic Compounds | MGLL, GK, LIPC | CA1 3332/4885ACE2 3055/4885FFAR1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.